Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Biogen Reiterates Byooviz Will Not Be Meaningful In 2022

Launches Outside Of The US Scheduled For Early 2023

  • News

Executive Summary

Biogen is looking for its ranibizumab biosimilar Byooviz to make a splash in 2023 as it continues to forecast falling biosimilars sales for 2022.

You may also be interested in...



Biosimilars Growth At Biogen Still Pending As Unfavorable Market Takes Its Toll

Biogen expects impending biosimilar launches to stimulate new growth, while unfavorable market conditions have taken their toll on the company.

Coherus Shakes Up Ranibizumab Competition With First Interchangeable US Biosimilar

Coherus BioSciences has heralded a “strategic inflection point” for the company after receiving USFDA approval for Cimerli as an interchangeable biosimilar rival to Lucentis. The firm has also revealed launch plans for the Bioeq-partnered ranibizumab product.

Biogen and Bio-Thera Report Progress On Tocilizumab

Biogen and Bio-Thera have revealed positive Phase III data for their proposed tocilizumab biosimilar rival to Actemra/RoAcetmra.

Table

View full table

Related Content

Generics Bulletin

Related Companies

Tags:
Latest News

Apobiologix Launches Pegfilgrastim Autoinjector In Canada

Regeneron ‘Shocked’ At Biogen Lucentis Biosimilar Sales

Science-Based Thinking Promises Global Progress On Biosimilars

Finnish Biosimilar Substitution Proposals Get Pushback From Industry

See All
UsernamePublicRestriction

Register

GB152067

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By